Eldred Rock Partners LLC grew its holdings in shares of Icon Plc (NASDAQ: ICLR) by 12.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 59,017 shares of the medical research company's stock after purchasing an additional 6,390 shares during

Coho Partners Ltd. trimmed its stake in shares of Icon Plc (NASDAQ: ICLR) by 34.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,503 shares of the medical research company's stock after selling 78,840 shares during

Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2

Bamco Inc. NY trimmed its holdings in shares of Icon Plc (NASDAQ: ICLR) by 2.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 690,623 shares of the medical research company's stock after selling 13,862 shares during the quarter.

California Public Employees Retirement System increased its position in shares of Icon Plc (NASDAQ: ICLR) by 4.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,062 shares of the medical research company's stock after acquiring an additional 7,107 shares

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC).

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered per.

ICON Public Limited Company ( ICLR ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants Barry Balfe - CEO & Director Nigel Clerkin - Chief Financial Officer Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division All right. Good morning, everybody.

Artisan Partners Limited Partnership boosted its stake in Icon Plc (NASDAQ: ICLR) by 67.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,184,870 shares of the medical research company's stock after acquiring an additional 2,893,946 shares during the period. Icon accounts for

Allworth Financial LP raised its holdings in Icon Plc (NASDAQ: ICLR) by 64.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,396 shares of the medical research company's stock after buying an additional 547 shares during the quarter. Allworth Financial LP's